End-of-day quote
Korea S.E.
03:30:00 10/06/2024 am IST
|
5-day change
|
1st Jan Change
|
31,400
KRW
|
+5.55%
|
|
-0.63%
|
0.00%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
13,858
|
14,219
|
16,032
|
28,472
|
EBITDA
1 |
1,461
|
2,380
|
2,695
|
6,241
|
EBIT
1 |
1,126
|
1,874
|
2,138
|
5,607
|
Operating Margin
|
8.13%
|
13.18%
|
13.33%
|
19.69%
|
Earnings before Tax (EBT)
1 |
1,476
|
1,594
|
2,247
|
5,572
|
Net income
1 |
1,475
|
1,623
|
2,121
|
4,844
|
Net margin
|
10.65%
|
11.42%
|
13.23%
|
17.01%
|
EPS
2 |
23,854
|
26,241
|
31,434
|
978.3
|
Free Cash Flow
|
-
|
1,534
|
153.5
|
-752.5
|
FCF margin
|
-
|
10.79%
|
0.96%
|
-2.64%
|
FCF Conversion (EBITDA)
|
-
|
64.44%
|
5.7%
|
-
|
FCF Conversion (Net income)
|
-
|
94.5%
|
7.24%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
4,000
|
Announcement Date
|
11/04/22
|
11/04/22
|
06/04/23
|
27/03/24
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
2,443
|
324
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
509
|
3,156
|
Leverage (Debt/EBITDA)
|
1.672
x
|
0.1362
x
|
-
|
-
|
Free Cash Flow
|
-
|
1,534
|
154
|
-752
|
ROE (net income / shareholders' equity)
|
-
|
20.1%
|
21.1%
|
33.4%
|
ROA (Net income/ Total Assets)
|
-
|
7.97%
|
7.91%
|
17.7%
|
Assets
1 |
-
|
20,374
|
26,826
|
27,389
|
Book Value Per Share
2 |
1,17,233
|
1,43,350
|
1,74,115
|
3,533
|
Cash Flow per Share
2 |
41,980
|
71,705
|
59,898
|
777.0
|
Capex
1 |
1,865
|
799
|
180
|
1,369
|
Capex / Sales
|
13.46%
|
5.62%
|
1.12%
|
4.81%
|
Announcement Date
|
11/04/22
|
11/04/22
|
06/04/23
|
27/03/24
|
|
1st Jan change
|
Capi.
|
---|
| 0.00% | 13Cr | | -0.28% | 9.23TCr | | -3.16% | 3.81TCr | | +64.83% | 2.65TCr | | -13.98% | 1.57TCr | | -5.40% | 1.34TCr | | -11.38% | 1.17TCr | | +156.85% | 977.87Cr | | -49.84% | 1.01TCr | | +2.32% | 883.9Cr |
Biopharmaceuticals
|